• KLAY INVESTMENT FILM – WIP 12 – Final Sequence_viewable0

Forging the Frontiers of Cranial and Facial Surgery

The Klay Platform is an AI driven, revolutionary 3D software platform offering an unprecedented level of accuracy, predictability and patient control for cranial and facial surgical procedures.

Learn more

ACCURATE, SEAMLESS AND PATIENT-CENTRIC

Our faces are our most unique and important visual assets. We believe in empowering every patient who needs to make a change to their head or face. In order to do so, the Klay Platform provides a real-time virtual tool for patient and doctor to collaboratively design the patient’s desired look and outcome.

The Klay Platform uses proprietary hardware and software solutions to plan, visualise, develop and execute procedures with unprecedented levels of control and accuracy. To have this ability to see the predicted outcome with such precision before surgery is exceptionally reassuring for patients and provides an invaluable tool for surgical teams.

About_Img

About

The Klay Platform is built on our founding surgeons’ two decades of research and execution in improving surgery to the head and face. We’ve solved some of the most complex global challenges in this domain and continue to develop tools to assist doctors and surgical teams plan and deliver healthcare solutions to a degree that wasn’t possible before.

Our aim with the platform is to put the patient in control, at the centre of the intervention, allowing them to design their optimal outcome with the professionals. Enabling surgeons to predict the future in cranial and facial surgery and then following through exactly as planned is the foundation of Klay.

Product

The Klay Platform provides surgeons and their patients a fully texturised, high resolution 3D-model of the patient’s face, bone and tissue by combining our photogrammetry scanning technology with CT scans. Surgeons can then perform virtual surgery on the facial model using the Klay suite of design tools to 'see' the desired outcome with their patients.

The predictive engine behind the virtualised cranial and facial procedures is powered by AI and Finite Element algorithms. This is next level technology, driven by a patient-centric focus and precision healthcare.

In Front of screens

Our Team

Senior management team

Owase Jeelani MPhil, MBA, FRCS
Owase Jeelani MPhil, MBA, FRCS Co-Founder, Inventor & Paediatric Neurosurgeon
David Dunaway FRCE, CBE
David Dunaway FRCE, CBE Co-Founder Chairman, Inventor & Craniofacial Surgeon
Jeremy Littman
Jeremy Littman Co-Founder & Chief Executive Officer
Hector Macleod
Hector Macleod Co-Founder & Head of Software Development
Ed Farrell
Ed Farrell Chief Operating Officer
  • Owase is a world-renowned paediatric neurosurgeon, philanthropist, inventor and entrepreneur based at Great Ormond Street Hospital in London. Owase was the Head of the Neurosurgery Division at GOSH from 2012 until 2018. He established it as one of the largest paediatric neurosurgery services in the world and one of the flagship services at GOSH. His leadership and work have brought substantial international recognition to GOSH and the NHS. Owase is a Principal Investigator of FaceValue, a UCL-based research team of scientists and biomedical engineers that design machine-learning algorithms to predict and improve surgical outcomes. He’s also the inventor of CranioXpandTM, a cranial distractor system to make surgery safer and more cost-effective. In 2018 Owase founded Gemini Untwined, a global charity set up to assist and treat Craniopagus twins. Since then he has led on 3 further sets of Craniopagus twin separation procedures. Owase was ranked in Time Magazine’s top 100 surgeons in the UK in 2011 and the top 100 paediatric specialists in the UK in 2012.
  • David is a global expert in Craniofacial Surgery and Cranial Morphometrics. He leads the Craniofacial Surgery Unit at Great Ormond Street hospital and is a Principal Investigator at FaceValue leading a team of biomedical and software engineers at UCL. His clinical and research focus over the past 25 years has been on developing devices and software platforms to improve outcomes in Craniofacial surgery. During his career, David has undertaken thousands of complex craniofacial procedures including four sets of Craniopagus twin separations. In 2016 he was awarded a CBE in recognition to his exceptional contribution to facial surgery, globally.
  • Jeremy previously founded Engenie, now Osprey Charging, an EV charging business, which realised a £35m equity investment in 2019 achieving an 8x multiple return for early investors. This led to him founding the Exagen Group, a Smart Clean Energy Generator developing and operating utility scale renewable energy and battery storage plants able to solve the electricity grid imbalance caused by the booming makret in renewable generation. His passion to contribute to a cleaner, healthier environment runs in parallel with Klay’s social mission to help improve patient’s wellbeing. Jeremy lends a mix of technical and commercial experience to the team, building the group into a sustainable, high-growth biotech venture.
  • Hector set up Glassworks in 1996 and helped build and establish the world’s first open architecture VFX facility in New York. Initially they provided specialist higher-end visual effects to producers of commercials and pop promos. Utilising the skills of the deeply talented teams of artists within the VFX business, they established a special projects division, creating real-time interactive bespoke products in AR, VR and holographic displays. This led to building Heartworks for UCLH. This was a medical simulation, created by model builders and animators, which assisted in the teaching of cardiac anatomy and manikin-based simulation in echocardiography. It was a global success that inspired the foundation and development of The Klay Platform.
  • Ed has over 25 years of operations experience gained through various industry roles with a particular emphasis on medical devices and diagnostics. From February 2013 to December 2021 Ed served as President/COO of Quotient Ltd (NASDAQ:QTNT) where he led the development and realisation of the MosaiQ platform from concept to commercialisation. During his time with Quotient, Ed also played a significant role in Quotient’s IPO on Nasdaq and follow-on share offerings raising over $500 million in funding for the development of Quotient’s MosaiQ platform. Prior to Quotient, Ed held senior positions in operations in United Kingdom, United States and Ireland with Siemens Healthcare Diagnostics. Before he joined Siemens, Ed worked in engineering roles at Ingersoll Rand and Intel and holds a Masters in Engineering Science degree from University College Dublin.
Owase Jeelani MPhil, MBA, FRCS
Owase Jeelani MPhil, MBA, FRCS Co-Founder, Inventor & Paediatric Neurosurgeon
  • Owase is a world-renowned paediatric neurosurgeon, philanthropist, inventor and entrepreneur based at Great Ormond Street Hospital in London. Owase was the Head of the Neurosurgery Division at GOSH from 2012 until 2018. He established it as one of the largest paediatric neurosurgery services in the world and one of the flagship services at GOSH. His leadership and work have brought substantial international recognition to GOSH and the NHS. Owase is a Principal Investigator of FaceValue, a UCL-based research team of scientists and biomedical engineers that design machine-learning algorithms to predict and improve surgical outcomes. He’s also the inventor of CranioXpandTM, a cranial distractor system to make surgery safer and more cost-effective. In 2018 Owase founded Gemini Untwined, a global charity set up to assist and treat Craniopagus twins. Since then he has led on 3 further sets of Craniopagus twin separation procedures. Owase was ranked in Time Magazine’s top 100 surgeons in the UK in 2011 and the top 100 paediatric specialists in the UK in 2012.
David Dunaway FRCE, CBE
David Dunaway FRCE, CBE Co-Founder Chairman, Inventor & Craniofacial Surgeon
  • David is a global expert in Craniofacial Surgery and Cranial Morphometrics. He leads the Craniofacial Surgery Unit at Great Ormond Street hospital and is a Principal Investigator at FaceValue leading a team of biomedical and software engineers at UCL. His clinical and research focus over the past 25 years has been on developing devices and software platforms to improve outcomes in Craniofacial surgery. During his career, David has undertaken thousands of complex craniofacial procedures including four sets of Craniopagus twin separations. In 2016 he was awarded a CBE in recognition to his exceptional contribution to facial surgery, globally.
Jeremy Littman
Jeremy Littman Co-Founder & Chief Executive Officer
  • Jeremy previously founded Engenie, now Osprey Charging, an EV charging business, which realised a £35m equity investment in 2019 achieving an 8x multiple return for early investors. This led to him founding the Exagen Group, a Smart Clean Energy Generator developing and operating utility scale renewable energy and battery storage plants able to solve the electricity grid imbalance caused by the booming makret in renewable generation. His passion to contribute to a cleaner, healthier environment runs in parallel with Klay’s social mission to help improve patient’s wellbeing. Jeremy lends a mix of technical and commercial experience to the team, building the group into a sustainable, high-growth biotech venture.
Hector Macleod
Hector Macleod Co-Founder & Head of Software Development
  • Hector set up Glassworks in 1996 and helped build and establish the world’s first open architecture VFX facility in New York. Initially they provided specialist higher-end visual effects to producers of commercials and pop promos. Utilising the skills of the deeply talented teams of artists within the VFX business, they established a special projects division, creating real-time interactive bespoke products in AR, VR and holographic displays. This led to building Heartworks for UCLH. This was a medical simulation, created by model builders and animators, which assisted in the teaching of cardiac anatomy and manikin-based simulation in echocardiography. It was a global success that inspired the foundation and development of The Klay Platform.
Ed Farrell
Ed Farrell Chief Operating Officer
  • Ed has over 25 years of operations experience gained through various industry roles with a particular emphasis on medical devices and diagnostics. From February 2013 to December 2021 Ed served as President/COO of Quotient Ltd (NASDAQ:QTNT) where he led the development and realisation of the MosaiQ platform from concept to commercialisation. During his time with Quotient, Ed also played a significant role in Quotient’s IPO on Nasdaq and follow-on share offerings raising over $500 million in funding for the development of Quotient’s MosaiQ platform. Prior to Quotient, Ed held senior positions in operations in United Kingdom, United States and Ireland with Siemens Healthcare Diagnostics. Before he joined Siemens, Ed worked in engineering roles at Ingersoll Rand and Intel and holds a Masters in Engineering Science degree from University College Dublin.
Skulls